H.C. Wainwright Maintains a Buy Rating on Stoke Therapeutics (STOK)

​Stoke Therapeutics, Inc. (NASDAQ:STOK) is one of the Hot Growth Stocks to Invest in Now. On October 10, Ananda Ghosh from H.C. Wainwright reiterated a Buy rating on Stoke Therapeutics, Inc. (NASDAQ:STOK) with a $35 price target.

​The analyst noted the promising potential of the company’s Zorevunersen for treating Dravet syndrome as one of the key reasons behind their bullish sentiment. Ghosh highlighted that the drug’s 36-month open-label extension data showed long-term reduction in major motor seizure frequency along with cognitive and behavioral improvements. The analyst believes these results suggest that the treatment has the potential to become the first disease-modifying therapy for Dravet syndrome.

​In addition, Zorevunersen differentiates itself from the existing treatments due to its primary focus on symptomatic relief.

​Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotech company that develops RNA-based medicines for treating various diseases by increasing protein expression. Zorevunersen is one of the company’s lead drugs.

While we acknowledge the potential of STOK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.